OnKure Therapeutics is a publicly listed company based in the US.  OnKure is focused on the development of PI3Ka mutant subtype inhibitors.  PI3Ka is a key oncogenic driver in a variety of cancers.  The company’s lead product, OKI-219, is in a Phase I clinical study in breast cancer. RiverVest portfolio company Reneo Pharmaceuticals merged with OnKure in 2024 and the company is listed on NASDAQ with the ticker: OKUR